Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Silent ischaemia common among women with coronary microvascular dysfunction

11 Sep 2020

Ambulatory ischaemia, particularly silent ischaemia (SI), occurs commonly among women with coronary microvascular dysfunction (CMD), a new study has found.

Researchers enrolled 36 women with CMD, with an average age of 57±10 years, who were made to undergo 24-hour 12-lead ambulatory electrocardiogram monitoring following discontinuation of anti-ischaemia medication. Symptoms and evidence of ischaemia were recorded. Sixteen age-matched controls (mean age, 51±20 years) were also enrolled.

Fourteen women in the CMD group had at least one episode of ST depression, yielding a rate of 39 percent. There were 26 episodes in total. In comparison, no such cases were reported in the matched controls. The resulting difference was statistically significant (p=0.002).

Of the 26 ST depression episodes, only three (12 percent) were symptomatic; the remaining 23 episodes were silent. The mean and peak heart rate at the onset of SI was 96±13 and 117±16 bpm, respectively.

Coronary reactivity testing (CRT) measures were comparable between those with and without ambulatory ischaemia. CRT likewise did not differ between patients with and without SI, such that those who had ≥2 CRT abnormalities did not show a greater burden of SI episodes than comparators with <2 abnormalities.

“To our knowledge, this is the first report on prevalence of SI in a population of women who have undergone CRT to diagnose CMD,” researchers said.

“Given the previously established adverse prognostic significance of SI in obstructive coronary artery disease, and the poor outcomes associated with CMD, clinical trials evaluating anti-ischemic medications should be considered in the CMD population,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.